Can-Fite BioPharma Ltd.(CANF)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2025-12-31.

Can-Fite BioPharma Ltd. (CANF) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. CANF is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $3.8m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2025), Can-Fite BioPharma Ltd. reports quarterly revenue of $405.0K, net income of $-9.8M, free cash flow of $-9.0M. Top institutional holders of CANF by reported 13-F value include CITADEL ADVISORS, RHUMBLINE ADVISERS, FIFTH THIRD BANCORP, based on the most recent SEC filings. CANF trades on the NYSE exchange and files with the SEC under CIK 1536196. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CANF daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Can-Fite BioPharma Ltd. directly from SEC EDGAR.